The HiLOT high-flow therapy trial| ResMed

The HiLOT trial

A man sleeping in bed while receiving home high-flow therapy treatment

Home high-flow therapy (HFT) has been shown to reduce acute exacerbation rates and hospital admissions in patients with chronic pulmonary obstructive disease (COPD)1,2. 

With the need to grow the level of evidence on the benefits of  ome HFT, HiLOT aims to evaluate the effect of using home HFT with long-term oxygen therapy (LTOT) during one year in people with COPD or interstitial lung disease (ILD), vs using LTOT alone.

Study objectives

The main objective is to evaluate the impact of home HFT with LTOT on mortality and hospitalisations in patients with COPD. The trial will also evaluate the benefit(s) of home HFT with LTOT on quality of life and symptoms and assess the cost effectiveness, compliance and tolerance of the therapy.

Patient population

A solid blue circle icon with line drawings of a person and clipboard with a cross on it inside, symbolising exclusion criteria.

Main inclusion criteria*:

• COPD patients on LTOT
• ILD patients on LTOT
• BMI <35kg/m2
• > 40 years

A solid blue circle icon with line drawings of a person and clipboard with a cross on it inside, symbolising exclusion criteria.

Main exclusion criteria*:

• Current treatment with HFT, non-invasive ventilation or CPAP
• BMI > 35kg/m2
• Hospitalisation in the last 2 weeks

Study details

A solid purple circle icon with a line drawing of a doctor inside, symbolising study investigators.

Study type

Prospective, multicentre, registry-based, randomised controlled trial with parallel groups.

A solid purple circle icon with a line drawing of a doctor inside, symbolising study investigators.

Primary investigators

Assoc. Professor Magnus Ekström, Department Respiratory Medicine, Skåne University Hospital Lund,  Sweden

A solid purple circle icon with a line drawing of a hand cupping a euro coin inside, symbolising sponsors.

Sponsor

Skåne University Hospital Lund, Sweden

Study design

a solid blue circle with three men inside and a plus in front of them, symbolising a group of patients

310** patients randomised in two groups:
The intervention group: Home HFT + LTOT
The control group: LTOT alone

A solid blue circle icon with a line drawing of a stopwatch inside, symbolising study timings.

The enrolment period will last 36 months, with a follow-up period of 12 months, for a total study duration of 48 months.

The study endpoints

Primary endpoint:
Time to first hospitalisation or all-cause death in the year following randomisation in COPD patients.

Secondary endpoints include:
• Symptoms
• Health-related quality of life
• Hospitalisations
• Exacerbations
• Cost effectiveness

14 centres

A graphical map of Sweden with pointers indicating where the 10 academic centres in the HiLOT study are

Sign up for our clinical newsletter

Sign up to receive clinical updates about COPD, high-flow therapy, non-invasive ventilation, remote monitoring and more. You can also visit our Clinical News page for a selection of the latest research in these areas.

Please answer the question above

Please answer the question above

Please answer the question above

By clicking on “Subscribe”, you will receive periodic emails from us. You also consent to the processing of your data by ResMed for this purpose. For further information about how ResMed processes your personal data, please visit our Privacy Notice.

Support for investigator-initiated research

ResMed believes in the need to support ethical, independent clinical research, conducted by qualified third-party investigators.

This content is intended for health professionals only

*Please see https://www.clinicaltrials.gov/study/NCT06247397  for further information

**270 COPD patients and 40 ILD patients

  1. Storgaard LH, et al. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. Int J Chron Obstruct Pulmon Dis 2018;13:1195-1205. DOI : 10.2147/COPD.S159666
  2. Rea H, et al. The clinical utility of long-term humidification therapy in chronic airway disease. Respir Med 2010;104:525-533. DOI : 10.1016/j.rmed.2009.12.016V

Content last updated: 04/2024